Jefferies analysts have issued a note stating that Bayer is facing multiple challenges that require the company to consider strategic options. The halt of a late-stage clinical trial for experimental cardiovascular drug asundexian has increased financial risk, while falling share prices increase sensitivity to rising provisions and potential trial losses in a legal battle over its Roundup weedkiller. This suggests that Bayer may need to sell assets and scrap dividends to buy time. However, this may not be enough to enable the large-scale investments needed in its pharma business, Jefferies warns. As a result, the firm has downgraded its recommendation on the stock from buy to hold. Following Monday’s heavy losses, shares are trading 0.3% higher. (adria.calatayud@dowjones.com) Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8.